创伤性脑损伤中是否应输注血小板逆转伤前抗血小板药物?系统评价与Meta分析
该系统评价与Meta分析检索MEDLINE和Cochrane Reviews数据库(建库至2024年3月),纳入11项研究,共1,326例接受血小板输注和5,391例未接受输注的创伤性脑损伤患者。接受血小板输注者伤情更重(平均格拉斯哥昏迷评分13.4±0.44 vs 14.2±0.26;平均损伤严重度评分20.7±0.9 vs 18±3.4)。汇总分析显示,血小板输注未显著改变死亡率(OR 1.40;95%CI 0.72-2.71)或血肿进展(OR 1.09;95%CI 0.37-3.20),但住院时间延长2.2天(95%CI 2.07-2.32)、ICU住院时间延长3.06天(95%CI 2.0-4.13)。作者认为现有结果不支持常规逆转伤前抗血小板药物以降低死亡率或血肿进展,并为随机对照试验提供了依据。
要点
- 汇总分析显示,血小板输注未显著降低死亡率(OR 1.40;95%CI 0.72-2.71)或血肿进展(OR 1.09;95%CI 0.37-3.20)。
- 接受血小板输注者住院时间延长2.2天(95%CI 2.07-2.32),ICU住院时间延长3.06天(95%CI 2.0-4.13)。
- 接受血小板输注者伤情更重:平均格拉斯哥昏迷评分13.4±0.44 vs 14.2±0.26,平均损伤严重度评分20.7±0.9 vs 18±3.4。
- 作者认为现有文献结果不支持常规逆转伤前抗血小板药物以降低死亡率或血肿进展。
- 作者建议开展随机对照试验,以获得更高级别证据来制定高质量循证指南。
适用人群与场景
- 创伤性脑损伤且伤前使用抗血小板药物的患者,比较接受与未接受血小板输注者。
研究设计与关键结果
- 系统评价与Meta分析,检索MEDLINE和Cochrane Reviews数据库(建库至2024年3月),纳入11项研究,共1,326例接受血小板输注和5,391例未接受输注的创伤性脑损伤患者。
- 接受血小板输注者伤情更重:平均格拉斯哥昏迷评分13.4±0.44 vs 14.2±0.26;平均损伤严重度评分20.7±0.9 vs 18±3.4。
- 血小板输注未显著改变死亡率(OR 1.40;95%CI 0.72-2.71)或血肿进展(OR 1.09;95%CI 0.37-3.20)。
- 血小板输注组住院时间延长2.2天(95%CI 2.07-2.32),ICU住院时间延长3.06天(95%CI 2.0-4.13)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析;证据等级:Level IV。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,现有文献结果不支持常规逆转伤前抗血小板药物以降低死亡率或血肿进展。
- 作者指出,对这类患者输注血小板可能不必要地延长ICU和住院时间。
- 作者认为本Meta分析为在伤前使用抗血小板药物的颅脑损伤患者中开展血小板输注随机对照试验提供了依据。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Platelet transfusion is a scarce resource in many trauma centers that is not without its own complications. Controversy exists in the literature regarding platelet transfusion in the setting of traumatic brain injury in patients on antiplatelet agents.
METHODS: A search of the MEDLINE and Cochrane Reviews databases was used to identify all studies examining platelet transfusion and antiplatelet agents related to traumatic brain injury published from inception to March 2024. Study selection, data extraction, and bias assessment were conducted independently by two reviewers. Heterogeneity was assessed via I2 statistic, and publication bias was evaluated using Newcastle Ottawa Scale for cohort studies. A meta-analysis was performed to estimate pooled treatment effects with 95% confidence intervals (CIs).
RESULTS: Of the 131 studies initially identified, 11 studies met the inclusion criteria comprising 1,326 patients who received platelet transfusion and 5,391 patients who did not. Across studies, patients receiving platelets were more severity injured than those who did not (mean Glasgow Coma Scale, 13.4 ± 0.44 vs. 14.2 ± 0.26; mean Injury Severity Score, 20.7 ± 0.9 vs. 18 ± 3.4). Pooled analysis found that receiving platelet transfusion did not significantly change the likelihood of mortality or hemorrhage progression (odds ratio, 1.40; 95% CI, 0.72-2.71; odds ratio, 1.09; 95% CI, 0.37-3.20, respectively). Both length of stay (LOS) and intensive care unit LOS were found to be significantly longer with platelet transfusion (2.2 days longer: 95% CI, 2.07-2.32; 3.06 days longer: 95% CI, 2.0-4.13).
CONCLUSION: The results currently available in the literature do not support the routine reversal of preinjury antiplatelet agents for reducing mortality or hemorrhage progression. Furthermore, the use of platelet transfusion in these patients may unnecessarily prolong intensive care unit and hospital LOS. This meta-analysis provides justification for randomized-controlled trials investigating the effects of platelet transfusion in head-injured patients on preinjury antiplatelet agents. Obtaining higher level of evidence will expedite the creation of high-quality evidence-based guidelines for the management of these complex patients.
LEVEL OF EVIDENCE: Systematic Review/Meta-analysis; Level IV.
参考来源
- Larson NJ, Rhone A, Chrenka E, et al. Should platelet transfusion be used to reverse preinjury antiplatelet agents in traumatic brain injury? A systematic review and meta-analysis. J Trauma Acute Care Surg. 2026. PMID: 41532957. doi:10.1097/TA.0000000000004827
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。